- SFG FRC 2027 | Program starts from 19th Dec. 2026 | Admissions open for Entrance Test Click Here to know more →
- Prelims Test Series (PTS) for Prelims 2027 starts 11th Oct. 2026 Click Here to know more →
- [Pre-order] Ethics Redbook 3rd Edition: Delivery starts from 10th October onwards Click Here to Read More →
- 21 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 11th Oct. Click Here to Read More →
Source: The post is based on the article “DRESS Syndrome: Painkiller Meftal can have adverse reactions; govt issues drug safety alert” published in “Business Standard” on 8th December 2023
Why in the News?
The Indian Pharmacopoeia Commission (IPC) has warned about risks linked to the painkiller Meftal. They have cautioned about possible harmful reactions with the drug such as a severe condition called DRESS syndrome.
What is DRESS Syndrome?
1) DRESS syndrome stands for Drug Rash with Eosinophilia and Systemic Symptoms.
2) It is a severe, idiosyncratic reaction to a drugs such as such as abacavir, allopurinol, and lamotrigine.
Note- Idiosyncratic drug reaction is used for unpredictable reactions that occur in only a small percentage of patients receiving the drug
3) It is characterised by a delayed onset of symptoms including fever, skin rash, lymphadenopathy (swelling of lymph nodes), eosinophilia (an increase in a type of white blood cells) and various systemic manifestations.
4) The syndrome has an estimated mortality rate of 10 per cent.
What is Meftal?
1) Meftal is an over-the-counter medication used to treat pain and inflammation.
2) It contains the active ingredient mefenamic acid, which belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs).
3) It is often prescribed for conditions like rheumatoid arthritis, menstrual pain, dental pain, inflammation, fever, etc.
4) Other commonly used NSAIDs include ibuprofen, naproxen, and aspirin
What is the Indian Pharmacopoeia Commission (IPC)?
UPSC Syllabus: Science and Technology
